热消融治疗意义未明甲状腺结节的疗效与安全性:系统综述与荟萃分析
本系统综述与荟萃分析纳入15项研究共1149个Bethesda III/IV类意义未明甲状腺结节,评估热消融的疗效与安全性。热消融或可作为不适合或拒绝手术患者的微创替代方案,但需长期随访。
要点
- 主要并发症发生率1.8%(21/1149),无转移报告;复发2.3%(26/1149),延迟手术0.3%(4/1149)。
- 水分离技术可显著改善6个月体积缩小率(p=0.03),较大结节更易复发。
核心结论
- 热消融可作为不适合或拒绝手术的意义未明甲状腺结节患者的微创替代方案,疗效与安全性较好。
- 但研究存在局限性、随访时间短及残留恶性风险,需谨慎随访,尤其对较大结节。
- 水分离等先进热消融技术可能通过提高完全消融几率来改善结局。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和COCHRANE数据库至2025年5月11日。
- 纳入标准为热消融治疗意义未明甲状腺结节、随访≥12个月且报告临床或安全性结局的研究。
- 排除病例报告、摘要和综述;由两名放射科医生独立提取数据并评估质量,采用RoBANS工具评价偏倚风险。
- 最终纳入15项研究,共1149个结节;采用随机效应模型合成合并估计值,以Higgins I2量化异质性。
主要发现
- 水分离技术显著改善6个月体积缩小率(p=0.03);较大结节更易复发。
- 主要并发症发生率为1.8%(21/1149),无转移报告。
- 复发率为2.3%(26/1149),延迟手术率为0.3%(4/1149),延迟手术中发现3例恶性。
关键数值与推荐
- 主要并发症:1.8%(21/1149);复发:2.3%(26/1149);延迟手术:0.3%(4/1149)。
- 水分离改善6个月体积缩小率的p值为0.03。
- 纳入研究随访时间至少12个月。
临床怎么用
- 对于不适合或拒绝手术的Bethesda III/IV类意义未明甲状腺结节患者,可考虑热消融作为微创替代方案。
- 热消融后需进行仔细随访,尤其是较大结节,因存在残留恶性风险和复发可能。
- 采用水分离等先进热消融技术可能提高完全消融几率,从而改善体积缩小率。
局限性
- 研究存在局限性,随访时间短。
- 存在残留恶性风险,需谨慎随访。
- 需要长期前瞻性研究和随机试验来确认热消融在临床实践中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The management of indeterminate thyroid nodules (ITNs), classified as Bethesda III and IV, is challenging due to biopsy limitations in distinguishing benign from malignant nodules. While diagnostic lobectomy is the standard, thermal ablation (TA) is increasingly considered for patients ineligible or unwilling to undergo surgery. This systematic review and meta-analysis therefore evaluate the efficacy and safety of TA for ITNs. Methods: A comprehensive search of MEDLINE, EMBASE, and COCHRANE databases was conducted through May 11, 2025, for studies on ITNs treated with TA, with ≥12 months of follow-up and reported clinical or safety outcomes. Case reports, abstracts, and reviews were excluded. Two radiologists independently performed data extraction and quality assessment. Outcomes included volume reduction rate (VRR), regrowth, delayed surgeries, malignancy detection, and complications. The Risk of Bias for Nonrandomized Studies (RoBANS) tool was used for quality assessment. A random-effects model synthesized pooled estimates, with heterogeneity quantified by Higgins' I2. Results: A total of 15 studies with 1149 nodules were analyzed, showing progressive VRR increase, plateauing at 48 months. The pooled 12-month VRR was 81.0% (confidence interval: 76.0-85.9%). Hydrodissection significantly improved VRR at 6 months (p = 0.03), while larger nodules were more prone to regrowth. Major complications occurred in 1.8% (21/1149), with no reported metastasis. Regrowth and delayed surgery occurred in 2.3% (26/1149) and 0.3% (4/1149), respectively, with three malignancies upon delayed surgery. Conclusions: TA may be considered a minimally invasive alternative for ITNs who are not candidates for or decline surgery, demonstrating favorable efficacy and safety. However, study limitations, short follow-up, and residual malignancy risk necessitate careful follow-up, particularly for larger nodules. Advanced TA techniques such as hydrodissection may enhance outcomes by increasing the likelihood of complete ablation. Long-term prospective studies and randomized trials are needed to confirm TA's role in clinical practice.
引用
- Lim H, Cho SJ, Jeong Y, et al. Efficacy and Safety of Thermal Ablation for Indeterminate Thyroid Nodules: A Systematic Review of the Literature and Meta-Analysis. Thyroid. 2025. PMID: 40658618. doi:10.1089/thy.2024.0679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。